Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Multi-arm, Open-label Study of MK-1045 in Combination With Zilovertamab Vedotin in Participants With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT07917754 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07917754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Multi-arm, Open-label Study of MK-1045 in Combination With Zilovertamab Vedotin in Participants With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
December 13, 2026
Completion date
March 13, 2037
Enrollment
470 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, lymphoma, large b-cell, diffuse

Arms

As registered; 2 arms.

  • Part 1 and Part 2: MK-1045 plus Zilovertamab vedotin (ZV) ExperimentalGranulocyte-colony stimulating factor (G-CSF), MK-1045, Rescue Medication - Biological, Rescue Medications - Drug, Zilovertamab vedotin

    Participants will receive escalating doses (2 to 120mg) of MK-1045 (or in Part 2, a dose of MK-1045 determined by Part 1) via intravenous infusion (IV) once weekly (q1w) for 48 weeks plus 1.5 or 1.75 mg/kg ZV via IV infusion once every 3 weeks (q3w) for 18 weeks. Participants may continue to receive MK-1045 once every 2 weeks (q2w) after 3 months if a Complete Response (CR) is achieved.

  • Part 2: Physician's Choice of Chemotherapy Active comparatorBendamustine, Lenalidomide, Polatuzumab vedotin, Rituximab, Rituximab biosimilar, Tafasitamab

    Participants will receive physician's choice of: 12 mg/kg tafasitamab per labeling instructions plus 25mg lenalidomide once daily (qd) from Days 1-21 of each cycle (each cycle is 28 days) for up to 12 cycles followed by 12 mg/kg tafasitamab monotherapy q2w if stable OR 1.8 mg/kg polatuzumab vedotin plus 90 mg/m\^2 bendamustine and 375 mg/m\^2 rituximab (or biosimilar) q3w for 6 cycles (each cycle is 21 days).

Primary endpoints

Registered primary outcome measures; 5 primary.

  • Part 1A: Number of Participants Who Experience Dose Limiting Toxicity (DLT) Up to approximately 42 days

    The following events, if considered drug related by the Investigator, will be considered a DLT: Grade (Gr) 5 toxicity; Gr 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Gr 4 thrombocytopenia of any duration; Gr 3 thrombocytopenia associated with any Gr2 or higher bleeding; Nonhematologic AEs ≥Gr 3 with exceptions; Gr 3 or Gr 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, or persists for \>72 hours; Gr 3 of 4 febrile neutropenia; Treatment-related toxicities that lead to discontinuation of study treatment or results in receiving incomplete planned doses of study treatment during DLT evaluation window (up to approximately 42 days).

  • Part 1A and 1B: Number of Participants Who Experience an Adverse Event (AE) Up to approximately 53 months

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

  • Part 1A and 1B: Number of Participants Who Discontinue Study Treatment Due to an AE Up to approximately 11 months

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

  • Part 1B: Objective Response Rate (ORR) Up to approximately 53 months

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 50% decrease in the sum of diameters of target lesions) per Lugano response criteria. The percentage of participants who experience CR or PR as assessed by physician investigator will be presented.

  • Part 2: Progression Free Survival (PFS) Up to approximately 53 months

    PFS is defined as the time from randomization to the first documented disease progression per Lugano response criteria by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first.

Lead sponsor's other trials

Merck Sharp & Dohme LLC, most recent start first.

Similar trials

Same condition (Lymphoma, Large B-Cell, Diffuse) and phase, most recent start first.